leadf
logo-loader
viewValiRx PLC

ValiRx unveils positive results from VAL401 Phase II lung cancer trial

ValiSeek CEO Dr Suzy Dilly tells Proactive their VAL401 treatment was found to have a “statistically significant” improvement in overall survival for patients with non-small cell lung cancer compared to those receiving no treatment.

The company had previously reported back in September that 2mg doses of VAL401 were “broadly safe and tolerated”, while the treatment also demonstrated “suitability of our proposed treatment paradigm”.

ValiSeek is a Joint Venture company between ValiRx Plc (LON:VAL) and Tangent Reprofiling Limited.

Quick facts: ValiRx PLC

Price: 21 GBX

AIM:VAL
Market: AIM
Market Cap: £13.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Anglo Pacific Group makes a transformational move by acquiring stream on the...

Anglo Pacific Group (TSE: APY- LSE: APF) CEO Julian Treger joined Steve Darling from Proactive with news the company has just announced the biggest deal the company has ever done, acquiring a stream on Vale’s Voisey’s Bay Nickel and Cobalt project in Newfoundland and Labrador for 205...

10 hours, 18 minutes ago

2 min read